Pseudomembranous Colitis Clinical Trial
Official title:
Addition of a Probiotic (Lactobacillus GG) to Metronidazole for the Treatment of Clostridium Difficile Associated Disease
The purpose of this study is to determine whether dietary supplementation with Lactobacillus GG will reduce the rate of failure or relapse following treatment of CDAD with metronidazole.
Clostridium difficile associated disease (CDAD), which nearly always follows antibiotic therapy, has become increasingly common and important in American hospitals, causing substantial morbidity and mortality. Metronidazole is the recommended treatment for this condition. We have recently reported (Clin Infect Dis, June 2005) that treatment with metronidazole is associated with a 22% rate of failure and 28% rate of relapse. No other medication has been shown to be more effective. There is a substantial theory and some limited data to suggest that dietary supplementation with non-pathogenic normal bowel bacteria will benefit these patients. Lactobacillus GG is the best-standardized and the most extensively studied of these agents. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00382304 -
A Study of the Absorption of GT267-004 in Patients With Clostridium Difficile-Associated Diarrhea
|
Phase 2 | |
| Completed |
NCT00304876 -
Fecal Bacterial Flora in Clostridium Difficile-Associated Diarrhea
|
N/A | |
| Completed |
NCT03427229 -
Fecal Microbiota Transplantation for Severe Clostridium Difficile Infection
|
Phase 2 | |
| Completed |
NCT00106509 -
A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C.Difficile - Associated Diarrhea
|
Phase 3 | |
| Completed |
NCT00304369 -
Response of Clostridium Difficile Infection to Metronidazole Therapy
|
N/A | |
| Completed |
NCT00304889 -
Vancomycin vs. Nitazoxanide to Treat Recurrent C. Difficile Colitis
|
Phase 3 | |
| Completed |
NCT00304408 -
Association Between Response to Treatment of C. Diff Colitis and Anti-C.Diff Toxin Antibody
|
Phase 4 | |
| Completed |
NCT00304356 -
Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Infection
|
Phase 3 | |
| Completed |
NCT00182429 -
Efficacy of Metronidazole Versus Metronidazole and Rifampin in CDAD Treatment
|
Phase 3 |